In The Claims

Please amend the claims as follows:

1. (ORIGINAL) A phenothiazinium compound of Formula (I):



(I)

wherein:

A and B each independently is



in which R' and R" each independently is an optionally substituted linear, branched or cyclic hydrocarbon group, or R' and R" together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring;

and where X^{P-} is a counteranion and P is 1, 2 or 3;

except for the compounds in which A and B are both either $-N(CH_3)_2$ or

$-N(CH_2CH_3)_2$ ~~for use in a treatment that requires removal, deactivation or killing~~

~~of unwanted tissues or cells~~.

2. (CURRENTLY AMENDED) A ~~Use of a~~ phenothiazinium compound of Formula (I):



(I)

wherein:

~~according to Claim 1 in which~~ A and B are each independently selected from



in which Z is CH_2, CH_2-C_{1-6}-alkyl, O, S, SO_2, NH, NCH_3, NC_2H_5, NCH_2CH_2OH, or $NCOCH_3$ and R^1 and R^2 are each independently linear or branched $C_nH_{2n}Y$, where n is 1-10, Y is H, F, Cl, Br, I, -OH, $-OCH_3$, $-OC_2H_5$, $-OC_3H_7$, -CN

or -$OCOCH_3$.

3. (CURRENTLY AMENDED) ~~Use of a~~The compound according to Claim 1 wherein the counteranion is selected from ~~any~~the group consisting of: F^-, Br^- Cl^-, I^-, NO_3^-, SCN^-, ClO_3^-, ClO_4^-, IO_3^-, BF_4^-, HSO_4^-, $H_2PO_4^-$, $CH_3SO_4^-$, N_3^-, SO_4^{2-}, HPO_4^{2-}, PO_4^{3-}, acetate, lactate, citrate, tartrate, glycolate, glycerate, glutamate, β-hydroxyglutamate, glucouronate, gluconate, malate and aspartate.

4. (CURRENTLY AMENDED) ~~Use of a~~The compound according to claim 1 wherein the counteranion is selected from ~~any~~ the group consisting of: Cl^-, Br^-, I^-, F^-, NO_3^-, HSO_4^-, $CH_3CO_2^-$, ~~or~~ a dianion~~, namely, SO_4^{2-} or HPO_4^{2-}, or~~ and a trianion ~~namely PO_4^{3-}~~.

5. (CURRENTLY AMENDED) ~~Use of a~~The compound according to Claim 2 in which A and B may be the same or different and R^1 and R^2 are selected independently from the group consisting of: ethyl, n-propyl, n-butyl, i-butyl, n-pentyl, i-pentyl, n-hexyl, $HO(CH_2)_2$-, 2-ethylpiperidino, 2-methylpyrrolidino and cyclohexyl.

6. (CURRENTLY AMENDED) ~~Use of a~~The compound according to Claim 2 in which A and B may be the same or different and R^1 and R^2 are selected independently from the group consisting of: ethyl, n-propyl, n-butyl, i-butyl, n-pentyl, i-pentyl, n-hexyl, 2-ethylpiperidino, 2-methylpyrrolidino and cyclohexyl.

7. (CURRENTLY AMENDED) ~~Use of a~~The compound according to Claim 2 in which A and B may be the same or different and R^1 and R^2 are selected independently from the group consisting of: ethyl, n-butyl, i-butyl, n-pentyl, i-pentyl, n-hexyl, 2-ethylpiperidino, 2-methylpyrrolidino and cyclohexyl.

8. (CURRENTLY AMENDED) ~~Use of a~~The compound according to claim 1 wherein A and B are the same and both R^1 and R^2 are n-propyl, n-butyl or n-pentyl.

9. (CURRENTLY AMENDED) ~~Use of the following~~The compound of Claim 1 which are moieties selected from the group consisting of:

3,7-(tetra-n-propylamino)-phenothiazin-5-ium;

3,7-(tetra-n-butylamino)-phenothiazin-5-ium;

3,7-(tetra-n-pentylamino)-phenothiazin-5-ium;

3,7-(tetra-iso-pentylamino)-phenothiazin-5-ium;

3-(N,N-di-n-butylamino)-7-(N,N-di-n-propylamino)-phenothiazin-5-ium;

3-(N,N-di-n-hexylamino)-7-(N,N-di-n-propylamino)-phenothiazin-5-ium;

3-(2-ethylpiperidino)-7-(N,N-di-n-pentylamino)-phenothiazin-5-ium;

3-(2-methylpyrrolidino)-7-(N,N-di-n-pentylamino)-phenothiazin-5-ium;

3,7-(N,N-tetra- iso-butylamino)-phenothiazin-5-ium;

3-(N,N-di-n-butylamino)-7-(N,N-di-iso-pentylamino)-phenothiazin-5-ium;

3-(N,N-diethanolamino)-7-(N,N-di-n-pentylamino)-phenothiazin-5-ium;

3-(N,N-diethylamino)-7-(N,N-di-n-propylamino)-phenothiazin-5-ium;

3-(N,N-di-n-pentylamino)-7-(N,N-di-n-propylamino)-phenothiazin-5-ium;

3-(N,N-di-n-butylamino)-7-(N,N-di-n-pentylamino)-phenothiazin-5-ium; and

3-((N-ethyl-N-cyclohexyl)———amino)-7((-N–ethyl)-N-cyclohexyl)———amino-phenothiazin-5-ium;

in which the counteranions are selected from the group consisting of: Cl^-, Br^- ~~or~~and I^-, —in a treatment that requires removal, deactivation or killing of unwanted tissues or cells.

10. (CURRENTLY AMENDED) A composition comprising one or more compounds of Formula (I):



(I)

wherein:

A and B each independently is



in which R' and R" each independently is an optionally substituted linear, branched or cyclic hydrocarbon group, or R' and R" together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring;

and where X^{P-} is a counteranion and P is 1, 2 or 3;

except for the compounds in which A and B are both either $-N(CH_3)_2$ or $-N(CH_2CH_3)_2$; and~~Formula I according to claims 1 to 9 together with~~

a diluent or excipient.

11. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1~~ to 9~~ for use as a medicament

12. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1~~ to 9~~ for use as an anticancer agent, an antibacterial or an antifungal or an antiviral.

12. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1~~ to 9~~ for use against microorganisms.

13. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1~~ to 9~~ for use against bacteria.

14. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1~~ to 9~~ for use against antibiotic resistant bacteria.

15. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1~~ to 9~~ for use as a PDT agent or a photodiagnostic agent.

16. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1 ~~to 9~~ for use as an anti-microbial treatment for skin and other local infections, for sterilisation of burn wounds and other lesions, and for the treatment of dental bacterial disease.

17. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1 ~~to 9~~ for use in the treatment of pre-cancerous conditions, cancer, ophthalmological disease including macular degeneration, vascular problems ~~such as cardiovascular disease~~, arteriosclerosis, ~~and~~ restenosis, ~~and~~ autoimmune diseases ~~such as rheumatoid arthritis~~, skin diseases ~~such as psoriasis, acne and excema~~, and other benign conditions ~~such as endometriosis and menorrhagia~~.

18. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1 ~~to 9~~ for use as a photoactivated antimicrobial agent for sterilisation of surfaces and fluids.

19. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1 ~~to 9~~ for use in photochemical internalisation.

20. (CURRENTLY AMENDED) ~~A~~The compound according to ~~any of~~ claims 1 ~~to 9~~ for use in photodetection and/or photodiagnosis.

21. (CURRENTLY AMENDED) A conjugate or composite formed between a compound of ~~Formula I according to claims 1 to 9~~ Formula (I):



(I)

wherein:

A and B each independently is



in which R' and R'' each independently is an optionally substituted linear, branched or cyclic hydrocarbon group, or R' and R'' together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring;

and where X^{P-} is a counteranion and P is 1, 2 or 3;

except for the compounds in which A and B are both either $-N(CH_3)_2$ or

$-N(CH_2CH_3)_2$;

-and a polymer.

22. (CURRENTLY AMENDED) (ORIGINAL) AThe conjugate or composite of claim 21 wherein the polymer includes anhydride and/or ester groups.

23. (CURRENTLY AMENDED) A compound formed by the reaction

between a compound ~~Formula I according to claims 1 to 9~~ Formula (I):



(I)

wherein:

A and B each independently is



in which R' and R" each independently is an optionally substituted linear, branched or cyclic hydrocarbon group, or R' and R" together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring;

and where X^{P-} is a counteranion and P is 1, 2 or 3;

except for the compounds in which A and B are both either $-N(CH_3)_2$ or

$-N(CH_2CH_3)_2$;

and a chlorotriazine derivative.

24. (ORIGINAL) A compound according to claim 23 wherein the chlorotriazine derivative is a polymer having chlorotriazine groups attached thereto.

25. (CURRENTLY AMENDED) ~~A~~The composition according to claim 21 further comprising ~~comprising a compound, conjugate or composite of any of claims 21 to 24 together with~~ a diluent or excipient.

26. (CURRENTLY AMENDED) A method of treating pre-cancerous conditions, cancer, ophthalmological disease ~~including macular degeneration~~, vascular problems ~~such as cardiovascular disease~~, arteriosclerosis ~~and~~, restenosis, ~~and~~ autoimmune diseases ~~such as rheumatoid arthritis~~, skin diseases ~~such as psoriasis, acne and excema~~, and other benign conditions ~~such as endometriosis and menorrhagia~~, the method comprising:

administering to a subject a therapeutically effective amount of a compound of Formula (I):



(I)

wherein:

A and B each independently is



in which R' and R" each independently is an optionally substituted linear,

branched or cyclic hydrocarbon group, or R' and R" together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring;

and where X^{P-} is a counteranion and P is 1, 2 or 3;

except for the compounds in which A and B are both either $-N(CH_3)_2$ or

$-N(CH_2CH_3)_2$; ~~any of claims 1 to 9~~ and

exposing said subject to light to render active said compound.

27. (CURRENTLY AMENDED) ~~A~~The method according to claim 26 wherein ~~the~~said compound ~~of any of claims 1 to 9~~ is administered and the light exposure is given up to 48 hours after a drug is initially administered.

28. (CURRENTLY AMENDED) ~~A~~The method according to claim 26 wherein ~~the~~said compound ~~of any of claims 1 to 9~~ is administered and the light exposure is given up to 3 hours after a drug is initially administered.

29. (CURRENTLY AMENDED) ~~A~~The method according to claim 26 wherein ~~said compound administered is as defined in claim 8 where~~ R^1 and R^2 are both n-propyl and said light exposure is given up to 10 minutes after a drug is initially administered.

30. (CURRENTLY AMENDED) ~~A~~The method according to ~~any one of~~ claims ~~28 and~~ 29 wherein light exposure is given within 1 minute after a drug is initially administered.

31. (CURRENTLY AMENDED) ~~A~~The method according to ~~to any one of~~ claims 28 ~~and 29~~, wherein light exposure is given at the point of drug administration.

32. (CURRENTLY AMENDED) ~~A~~The method according to claim 26 wherein ~~the compound administered is as defined in claim 8 where~~ R^1 and R^2 are both n-pentyl and said light exposure is given up to one hour after a drug is initially administered.

33. (CURRENTLY AMENDED) A method of treatment of microbial infections, burn wounds and other lesions and of dental bacterial disease, the method comprising systemic administration or applying to the area to be treated a therapeutically effective amount of a compound of ~~any of claims 1 to 9~~ Formula (I):



(I)

wherein:

A and B each independently is



in which R' and R" each independently is an optionally substituted linear, branched or cyclic hydrocarbon group, or R' and R" together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring;

and where X^{P-} is a counteranion and P is 1, 2 or 3;

except for the compounds in which A and B are both either $-N(CH_3)_2$ or

$-N(CH_2CH_3)_2$; and

exposing said area to light to render active said compound.

34. (CURRENTLY AMENDED) ~~A~~The method according to claim 33 wherein ~~the compound administered is as defined in claim 8~~ where R^1 and R^2 are n-butyl.

35. (CURRENTLY AMENDED) A method of sterilising a surface or a fluid comprising:

contacting or applying ~~the~~a compound ~~according to any of claims 1 to 9~~ of the Formula (I):



(I)

wherein:

A and B each independently is



in which R' and R" each independently is an optionally substituted linear, branched or cyclic hydrocarbon group, or R' and R" together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring;

and where X^{P-} is a counteranion and P is 1, 2 or 3;

except for the compounds in which A and B are both either $-N(CH_3)_2$ or $-N(CH_2CH_3)_2$ to said surface or fluid; and

activating said compound by means of light.

36. (CURRENTLY AMENDED) An article having at least one surface to which is attached a compound, conjugate or composite ~~according to any of claims 1 to 9, 21, 22, 23 and 24.~~ comprising a compound of Formula (I):



(I)

wherein:

A and B each independently is



in which R' and R" each independently is an optionally substituted linear, branched or cyclic hydrocarbon group, or R' and R" together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring;

and where X^{P-} is a counteranion and P is 1, 2 or 3;

except for the compounds in which A and B are both either $-N(CH_3)_2$ or $-N(CH_2CH_3)_2$.

37. (ORIGINAL) ~~An~~The article according to claim 36 wherein attachment is by covalent bonds or by intermolecular interactions.

38. (CURRENTLY AMENDED) ~~An~~The article according to claim 36 ~~or claim 37~~, wherein said article ~~which~~ is a medical device.

39 (CURRENTLY AMENDED) ~~An~~The article according to claim 36 ~~or claim 37~~ which is for use in the food industry.

40. (CURRENTLY AMENDED) A method for sterilising fluids in which the fluid is contacted with a conjugate or composite formed between:

a compound of ~~Formula I~~ Formula (I):



(I)

wherein:

A and B each independently is



in which R' and R" each independently is an optionally substituted linear, branched or cyclic hydrocarbon group, or R' and R" together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring;

and where X^{P-} is a counteranion and P is 1, 2 or 3;

except for the compounds in which A and B are both either $-N(CH_3)_2$ or

$-N(CH_2CH_3)_2$; and

a polymer whilst the conjugate or composite is illuminated.

41. (ORIGINAL) A compound of Formula I



wherein:

A and B each independently is



in which R' and R" each independently is a linear, branched or cyclic hydrocarbon group, or R' and R" together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring;

and where X^{P-} is a counteranion and P is 1, 2 or 3;

except for the compounds in which A and B are the same and are selected from the group consisting of:- $-N(CH_3)_2$, $-N(CH_2CH_3)_2$, $N(n\text{-}Pr)_2$, $-N(n\text{-}Bu)_2$, -

$N(n\text{-}Pent)_2$, $-N(n\text{-}Hex)_2$, $-N(n\text{-}Hept)_2$, piperidino, $-N(CH_2CH_2OH)_2$, and -N(diethylhexyl)$_2$,

and not including those in which A is selected from $-N(Me)_2$ or $-N(Et)_2$ and B is selected from the group consisting of: $-N(CH_2CH_2OH)_2$, piperidino, morpholino, thiomorpholino, $-N(Et)_2$, -N(MeEt), and $-N(Me)_2$.

42. (CURRENTLY AMENDED) The compound according to claim 41 wherein said compound is a ~~following~~ moieties selected from the group consisting of:

3,7-(tetra-iso-pentylamino)-phenothiazin-5-ium;

3-(N,N-di-n-butylamino)-7-(N,N-di-n-propylamino)-phenothiazin-5-ium;

3-(N,N-di-n-hexylamino)-7-(N,N-di-n-propylamino)-phenothiazin-5-ium;

3-(2-ethylpiperidino)-7-(N,N-di-n-pentylamino)-phenothiazin-5-ium;

3-(2-methylpyrrolidino)-7-(N,N-di-n-pentylamino)-phenothiazin-5-ium;

3,7-(N,N-tetra- iso-butylamino)-phenothiazin-5-ium;

3-(N,N-di-n-butylamino)-7-(N,N-di-iso-pentylamino)-phenothiazin-5-ium;

3-(N,N-diethanolamino)-7-(N,N-di-n-pentylamino)-phenothiazin-5-ium;

3-(N,N-diethylamino)-7-(N,N-di-n-propylamino)-phenothiazin-5-ium;

3-(N,N-di-n-pentylamino)-7-(N,N-di-n-propylamino)-phenothiazin-5-ium;

3-(N,N-di-n-butylamino)-7-(N,N-di-n-pentylamino)-phenothiazin-5-ium; and

3-((N-ethyl-N-cyclohexyl)———amino)-7((-N–ethyl)-N-cyclohexyl)———amino-phenothiazin-5-ium;

in which the counteranions are selected from the group consisting of: Cl^-, Br^-

~~or~~and I".